Posted by: I485 September 7, 2017
Login in to Rate this Post:
0 
? 
?
ADAP boom ! , Nice news came out of ADAP this morning.
GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO
Adaptimmune will receive up to £48 million (~$61 million) from GSK over the course of the transition period. This includes development milestones of up to £18 million (~$23 million) and the option payment of £30 million (~$38 million), which also allows GSK to nominate two additional targets following completion of the transition. Successful continuation of development and subsequent commercialization of NY-ESO would trigger additional payments for development milestones, tiered sales milestones, and mid-single to low double-digit royalties on worldwide net sales.
https://globenewswire.com/news-release/2017/09/07/1113946/0/en/GSK-Exercises-Option-over-SPEAR-T-cell-Therapy-Program-Targeting-NY-ESO.html
GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO
Adaptimmune will receive up to £48 million (~$61 million) from GSK over the course of the transition period. This includes development milestones of up to £18 million (~$23 million) and the option payment of £30 million (~$38 million), which also allows GSK to nominate two additional targets following completion of the transition. Successful continuation of development and subsequent commercialization of NY-ESO would trigger additional payments for development milestones, tiered sales milestones, and mid-single to low double-digit royalties on worldwide net sales.
https://globenewswire.com/news-release/2017/09/07/1113946/0/en/GSK-Exercises-Option-over-SPEAR-T-cell-Therapy-Program-Targeting-NY-ESO.html